The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive biliary tract
The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive biliary tract
האישור ניתן ל-zanidatamab-hrii, הידוע גם כ-Ziihera, נוגדן דו-ספציפי המכוון ל-HER2. הוא מיועד לחולים עם סרטן דרכי המרה חיובי ל-HER2 שאינו ניתן לכריתה (לא ניתן להסרה בניתוח) או גרורתי (התפשט לחלקים
In a report released today, Peter Welford from Jefferies maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF270.00. The company’s shares
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Premier (PINC – Research Report) and Roche Holding AG (RHHVF – Research Report).
Premier (PINC)
In a report issued on November 15, Michael Cherny from Leerink Partners maintained a Hold rating on Premier, with a price target of $23.00. The company’s shares closed last Monday at $22.39.
According to TipRanks.com, Cherny is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Premier with a $21.25 average price target, a -5.6% downside from current levels. In a report issued on November 5, Canaccord Genuity also maintained a Hold rating on the stock with a $21.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Roche Holding AG (RHHVF)
Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on Roche Holding AG today and set a price target of CHF250.00. The company’s shares closed last Monday at $285.04.
According to TipRanks.com, Papadakis is a 4-star analyst with an average return of
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $323.78.
Read More on PINC:
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, companion diagnostic test to be made widely available